Read more
6:08 PM · 3 February 2021

Vaxart shares plummet 50% on disappointing vaccine news

-
-
Open account Download free app

Vaxart (VXRT.US) stock plunged more than 50% during today's session after its experimental oral Covid vaccine showed disappointing preliminary data from its Phase 1 study. The biotechnology company announced that the vaccine was generally well-tolerated, however neutralizing antibodies were not detected among the 20 study participants who received two doses of the drug. Neutralizing antibodies bind to viruses in a way that prevents them from replicating. The company said no severe adverse events were reported in the phase one trial, with side effects generally being mild. Vaxart is still confident that its tablet will not only be able to treat the coronavirus but also handle the emerging new strains of the virus.  “Our Phase I results highlight the importance of our differentiated vaccine design, as they suggest VXA-CoV2-1 could have broad activity against existing and future coronavirus strains," Chief Executive Andrei Floroiu said in a statement. Vxart’s Covid vaccine is in a small tablet and can be shipped and stored at room temperature, unlike Pfizer and Moderna’s vaccines.

Vaxart (VXRT.US) launched today’s session with a massive bearish price however buyers managed to find some support at the $8.95 level which is additionally strengthened by 50 SMA (green line). Source: xStation5

6 March 2026, 6:49 PM

Boeing gains amid news about potential huge 737 MAX order from China 📈

6 March 2026, 4:17 PM

Wall Street tries to stop the deeper decline 🗽Marvell Technology jumps 10%

6 March 2026, 1:26 PM

RyanAir shares under pressure amid Middle East conflict 📉

5 March 2026, 12:50 PM

Stock of the Week: Broadcom Driven by AI Sets Records

Join over 2 000 000 XTB Group Clients from around the world
The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits